Skip to main content
Cosma Spolka Akcyjna logo

Cosma Spolka Akcyjna — Investor Relations & Filings

Ticker · COS ISIN · PLVBN0000015 LEI · 259400QHISD311JE0I22 WAR Manufacturing
Open in API
Filings indexed 6 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country PL Poland
Listing WAR COS

About Cosma Spolka Akcyjna

http://www.cosma.pl

Cosma Spolka Akcyjna specializes in the hemp and cannabis sector, operating with an integrated production and supply model. The company's core activities involve the manufacturing and distribution of products derived from hemp. Its portfolio includes professional dietary supplements, such as the Cosma Cannabis and Full Spectrum lines, which are based on natural hemp extracts. In addition to consumer supplements, Cosma produces pharmaceutical raw materials and medical-grade cannabis products for the pharmaceutical market. The company also offers a product line for animals under the Green Paw brand.

Recent filings

Filing Released Lang Actions
Wydanie pozytywnej decyzji w zakresie pozwolenia na dopuszczenie do obrotu surowca farmaceutycznego - Content (PL)
Regulatory Filings Classification · 1% confidence The document is an announcement by the board of Cosma S.A. informing about receipt of a regulatory permit from the President of the Office for Registration of Medicinal Products for a pharmaceutical raw material. It is neither a financial report nor a corporate transaction notice but a general regulatory update that does not fit any more specific category. This aligns with the “Regulatory Filings” fallback category (RNS).
2026-04-22 Polish
zal02_FormularzA_6.pdf
Major Shareholding Notification Classification · 1% confidence The document is a Polish “Zawiadomienie na podstawie art. 69 ust. 1 lub 2 oraz art. 69a ust. 1 lub 3 ustawy o ofercie (wypełnia akcjonariusz)”, detailing the shareholder’s direct holdings before and after a capital increase, crossing the 15% voting threshold. It reports pre- and post-transaction share counts, percentages of capital and votes, and cites statutory notification requirements under the Offer Act. This clearly matches a Significant/Major Shareholding Notification.
2026-03-23 Polish
zal01_FormularzA.pdf
Major Shareholding Notification Classification · 1% confidence The document is a formal notification by a shareholder under Polish securities law (“ustawa o ofercie”), detailing changes in shareholding percentages before and after a capital increase. It reports the direct holding levels, percentage of capital and voting rights, and the reason for the notification under Articles 69 and 69a. This matches a Major Shareholding Notification, where significant share ownership changes are declared.
2026-03-23 Polish
Dwa zawiadomienia o zmianie udziału w głosach - Content (PL)
Major Shareholding Notification Classification · 1% confidence The document is a company announcement that it received notifications under the Public Offering Act regarding changes in the percentage of voting rights held by specific investors. This aligns with the definition of a Major Shareholding Notification (MRQ) reporting changes in significant share ownership levels.
2026-03-23 Polish
Zawarcie umowy na wyłączną dystrybucję produktów marki Green Paw na terenie Szwajcarii - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement from the management of Cosma S.A. regarding the signing of a distribution agreement with BioPetFood GmbH. It details the nature of the contract, the territory, and the duration. Since it is a specific corporate announcement regarding a business development/contract that does not fit into the other specialized categories like M&A or financial reporting, it falls under the general regulatory announcement category.
2026-01-30 Polish
Wydanie pozytywnej decyzji w zakresie pozwolenia na dopuszczenie do obrotu surowca farmaceutycznego - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement from Cosma S.A. regarding the receipt of a marketing authorization for a pharmaceutical product. It details the regulatory approval process, the strategic partnership involved, and the expected impact on future business operations. As it is a formal regulatory disclosure of a material event (not a financial report, proxy, or meeting notice), it falls under the general regulatory filing category.
2026-01-30 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.